Paper · 41830752

Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2- bone-only metastatic breast cancer.

Brufsky A and 9 others. Breast, 2026. Cited by 0 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2- bone-only metastatic breast cancer. Papers, record 41830752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41830752

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2- bone-only metastatic breast cancer.; PubMed
Journal: Breast; PubMed
Year: 2026; PubMed
Publication types: Journal Article; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/41830752/; PubMed
DOI: https://doi.org/10.1016/j.breast.2026.104744; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC12996934/; PubMed
The journal: https://conductscience.org/library/journal-index/9213011; PubMed
Citations, by iCite: 0; iCite
Revised in PubMed: 2026-08-13; PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Brufsky A	Adam
2	Layman RM	Rachel M
3	Liu X	Xianchen
4	Li B	Benjamin
5	McRoy L	Lynn
6	Cohen AB	Aaron B
7	Estevez M	Melissa
8	Cottu P	Paul
9	Curigliano G	Giuseppe
10	Rugo HS	Hope S

Source PubMed

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Piperazines	Major topic
Pyridines	Major topic
Breast Neoplasms	Major topic
Aromatase Inhibitors	Major topic
Antineoplastic Combined Chemotherapy Protocols	Major topic
Bone Neoplasms	Major topic
Humans
Female
Retrospective Studies
Erb-b2 Receptor Tyrosine Kinases
Middle Aged
Aged
Treatment Outcome
Progression-Free Survival
Adult
Receptors, Estrogen
Receptors, Progesterone

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

Trial	Title	The trial lists it as	Named in the paper's record
NCT06495164	A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer	Derived from the trial	Yes

Source ClinicalTrials.gov

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

Kind	PMID	Title	In Papers
Erratum in	41,936,467	Corrigendum to "Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2- bone-only metastatic breast cancer" [The Breast 86 (2026) 104744].	https://conductscience.org/library/papers/41936467

Source PubMed

References48

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	33,411,622	Comparisons of Real-World Time-to-Event End Points in Oncology Research.	JCO Clin Cancer Inform	2021	https://conductscience.org/library/papers/33411622	PubMed
2	37,487,056	Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer.	Oncologist	2023	https://conductscience.org/library/papers/37487056	PubMed
3	17,785,994	Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter study.	Oncology	2006	https://conductscience.org/library/papers/17785994	PubMed
4	30,310,523	Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis.	J Cancer	2018	https://conductscience.org/library/papers/30310523	PubMed
5	32,783,178	Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials.	Breast Cancer Res Treat	2020	https://conductscience.org/library/papers/32783178	PubMed
6	39,754,979	Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting.	ESMO Open	2025	https://conductscience.org/library/papers/39754979	PubMed
7	33,663,223	CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies.	Future Oncol	2021	https://conductscience.org/library/papers/33663223	PubMed
8	17,062,708	Clinical features of metastatic bone disease and risk of skeletal morbidity.	Clin Cancer Res	2006	https://conductscience.org/library/papers/17062708	PubMed
9	37,841,423	Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older.	Front Oncol	2023	https://conductscience.org/library/papers/37841423	PubMed
10	31,717,791	Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials.	Cancers (Basel)	2019	https://conductscience.org/library/papers/31717791	PubMed

1 to 10 of 48

See all 48 references

Cited by0

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

None in this release.

Genes8

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
CYP19A1	1,588	PubTator's text mining	https://conductscience.org/library/genes/1588	NCBI Gene
ERBB2	2,064	PubTator's text mining	https://conductscience.org/library/genes/2064	NCBI Gene
EREG	2,069	PubTator's text mining	https://conductscience.org/library/genes/2069	NCBI Gene
ESR1	2,099	PubTator's text mining	https://conductscience.org/library/genes/2099	NCBI Gene
MFSD11	79,157	PubTator's text mining	https://conductscience.org/library/genes/79157	NCBI Gene
NR4A1	3,164	PubTator's text mining	https://conductscience.org/library/genes/3164	NCBI Gene
PGR	5,241	PubTator's text mining	https://conductscience.org/library/genes/5241	NCBI Gene
SHCBP1	79,801	PubTator's text mining	https://conductscience.org/library/genes/79801	NCBI Gene

Drugs3

The drugs whose trials, in the Pipelines release, list the paper.

Drug	ChEMBL ID	The trials list it as	Trials	In Drugs and targets	Source
PALBOCICLIB	CHEMBL189963	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL189963	ChEMBL
ABEMACICLIB	CHEMBL3301610	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL3301610	ChEMBL
RIBOCICLIB	CHEMBL3545110	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL3545110	ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41830752

GET https://conductscience.org/api/papers/v1/41830752/references?page=2

API reference For AI assistants